Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 520,143
  • Shares Outstanding, K 83,490
  • Annual Sales, $ 170 K
  • Annual Income, $ -23,300 K
  • 36-Month Beta 2.60
  • Price/Sales 2,996.77
  • Price/Cash Flow 0.00
  • Price/Book 2.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.66 +7.77%
on 08/10/17
7.07 -13.72%
on 07/19/17
-0.68 (-10.03%)
since 07/18/17
3-Month
5.66 +7.77%
on 08/10/17
7.68 -20.57%
on 07/17/17
-1.09 (-15.16%)
since 05/18/17
52-Week
1.88 +224.47%
on 09/01/16
10.54 -42.13%
on 03/13/17
+3.84 (+169.91%)
since 08/18/16

Most Recent Stories

More News
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company's US Presence

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US....

VKTX : 1.01 (+1.00%)
AUPH : 6.10 (-0.16%)
BIND : 0.78 (-10.34%)
SHPG : 145.55 (-1.62%)
VTAE : 21.00 (+0.05%)
BUYINS.NET: AUPH SqueezeTrigger Price is $5.92. There is $67,309,688 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in real time and just received an alert that AUPH is crossing above its primary SqueezeTrigger Price, the price that...

AUPH : 6.10 (-0.16%)
Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights

--Cash of $190 million as of June 30, 2017

AUP.TO : 7.68 (-0.65%)
AUPH : 6.10 (-0.16%)
Today's Research Reports on Aphria Inc., Aurinia Pharmaceuticals Inc., CRH Medical Corporation and Knight Therapeutics Inc.

NEW YORK, NY / ACCESSWIRE / August 1, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register...

AUPH : 6.10 (-0.16%)
APH.TO : 5.84 (-0.68%)
CRHM : 2.60 (unch)
Breakfast Technical Briefing on Biotech Stocks -- Aurinia Pharma, Esperion Therapeutics, Paratek Pharma, and Verastem

If you want a Stock Review on AUPH, ESPR, PRTK, or VSTM then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Focus is on the Biotech industry, which...

ESPR : 44.74 (-0.53%)
AUPH : 6.10 (-0.16%)
PRTK : 19.45 (-1.27%)
VSTM : 3.17 (+0.63%)
Aurinia Resolves Temporary Non-Compliance with Nasdaq's Audit Committee Composition Rule

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced the receipt of a letter from The NASDAQ Stock Market LLC, regarding the Company's recent...

AUP.TO : 7.68 (-0.65%)
AUPH : 6.10 (-0.16%)
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock on the back of its high implied volatility

AUPH : 6.10 (-0.16%)
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the...

VKTX : 1.01 (+1.00%)
AUPH : 6.10 (-0.16%)
SHPG : 145.55 (-1.62%)
venBio Global Strategic Fund, L.P. Announces Update to Stake in Aurinia Pharmaceuticals Inc.

SAN FRANCISCO, CALIFORNIA--(Marketwired - July 5, 2017) - venBio Global Strategic Fund, L.P. ("venBio") announced today that as a result of the closing on March 14, 2017 of a public offering (the "Offering")...

AUPH : 6.10 (-0.16%)
Aurinia Announces Results of Annual General Meeting

Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the six incumbent directors of the Company were elected at the Company's annual...

AUP.TO : 7.68 (-0.65%)
AUPH : 6.10 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Support & Resistance

2nd Resistance Point 6.28
1st Resistance Point 6.19
Last Price 6.10
1st Support Level 6.01
2nd Support Level 5.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.